Total Payments
$10,234
2024 Payments
$275.42
Companies
19
Transactions
84
Medicare Patients
3,402
Medicare Billing
$635,852
Payment Breakdown by Category
Other$6,647 (65.0%)
Food & Beverage$3,254 (31.8%)
Education$321.97 (3.1%)
Travel$11.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,150 | 6 | 50.3% |
| Food and Beverage | $3,254 | 72 | 31.8% |
| Honoraria | $1,497 | 1 | 14.6% |
| Education | $321.97 | 4 | 3.1% |
| Travel and Lodging | $11.00 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan Inc. | $5,944 | 35 | $0 (2019) |
| La Jolla Pharmaceutical Company | $1,786 | 5 | $0 (2024) |
| GlaxoSmithKline, LLC. | $726.19 | 7 | $0 (2024) |
| Astellas Pharma US Inc | $642.68 | 8 | $0 (2023) |
| Merck Sharp & Dohme LLC | $241.11 | 10 | $0 (2024) |
| Theravance Biopharma Inc. | $147.18 | 2 | $0 (2017) |
| Ferring Pharmaceuticals Inc. | $132.88 | 1 | $0 (2023) |
| ABBVIE INC. | $125.00 | 1 | $0 (2023) |
| Melinta Therapeutics, Inc. | $125.00 | 1 | $0 (2018) |
| US WorldMeds, LLC | $116.63 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $275.42 | 5 | GlaxoSmithKline, LLC. ($211.61) |
| 2023 | $971.28 | 12 | GlaxoSmithKline, LLC. ($514.58) |
| 2022 | $1,832 | 6 | La Jolla Pharmaceutical Company ($1,636) |
| 2021 | $200.88 | 6 | La Jolla Pharmaceutical Company ($126.00) |
| 2020 | $49.87 | 3 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($35.48) |
| 2019 | $1,736 | 19 | Allergan Inc. ($1,458) |
| 2018 | $1,946 | 18 | Allergan Inc. ($1,506) |
| 2017 | $3,222 | 15 | Allergan Inc. ($2,981) |
All Payment Transactions
84 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $118.95 | General |
| 09/04/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $13.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/22/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $92.66 | General |
| 03/14/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $23.88 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 02/06/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/06/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/01/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/13/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $116.30 | General |
| 10/12/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $132.88 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/27/2023 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $113.35 | General |
| Category: Infectious Diseases | ||||||
| 09/12/2023 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $29.08 | General |
| Category: GI | ||||||
| 08/23/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $162.45 | General |
| 07/06/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/30/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $20.89 | General |
| 06/29/2023 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: VIROLOGY | ||||||
| 06/21/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $116.14 | General |
| 03/23/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $98.80 | General |
| 11/10/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.99 | General |
| 10/12/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $79.99 | General |
| 06/28/2022 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA, RECARBRIO | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/06/2022 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Honoraria | Cash or cash equivalent | $1,497.00 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 03/16/2022 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $128.15 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 03/16/2022 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Travel and Lodging | In-kind items and services | $11.00 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 08/14/2021 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $126.00 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 07/28/2021 | Merck Sharp & Dohme Corporation | DIFICID (Drug), RECARBRIO | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 789 | 1,366 | $476,922 | $146,932 |
| 2022 | 6 | 860 | 1,573 | $537,670 | $162,207 |
| 2021 | 6 | 883 | 1,704 | $580,695 | $175,472 |
| 2020 | 5 | 870 | 1,517 | $524,105 | $151,241 |
Total Patients
3,402
Total Services
6,160
Medicare Billing
$635,852
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 309 | 813 | $231,932 | $74,406 | 32.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 349 | 384 | $191,706 | $51,153 | 26.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 55 | 79 | $24,509 | $10,988 | 44.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 56 | $14,375 | $5,225 | 36.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 18 | 18 | $8,475 | $3,082 | 36.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $5,925 | $2,077 | 35.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 325 | 922 | $262,770 | $72,763 | 27.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 373 | 428 | $214,000 | $65,159 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 75 | 121 | $30,250 | $12,163 | 40.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 33 | 43 | $12,900 | $6,034 | 46.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 34 | 34 | $12,750 | $4,354 | 34.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 25 | $5,000 | $1,735 | 34.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 342 | 1,083 | $308,870 | $87,041 | 28.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 412 | 457 | $228,500 | $70,681 | 30.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 80 | 107 | $26,750 | $10,870 | 40.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 23 | 29 | $8,700 | $4,191 | 48.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $4,875 | $1,741 | 35.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 13 | 15 | $3,000 | $950.04 | 31.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 406 | 457 | $228,500 | $68,622 | 30.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 321 | 863 | $245,955 | $67,350 | 27.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 78 | 121 | $30,250 | $9,743 | 32.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 24 | 24 | $9,000 | $2,850 | 31.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 41 | 52 | $10,400 | $2,675 | 25.7% |
About Dr. Xolani Mdluli, MD
Dr. Xolani Mdluli, MD is a Internal Medicine healthcare provider based in Palm Springs, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2007. The National Provider Identifier (NPI) number assigned to this provider is 1043418023.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Xolani Mdluli, MD has received a total of $10,234 in payments from pharmaceutical and medical device companies, with $275.42 received in 2024. These payments were reported across 84 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($5,150).
As a Medicare-enrolled provider, Mdluli has provided services to 3,402 Medicare beneficiaries, totaling 6,160 services with total Medicare billing of $635,852. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease
- Location Palm Springs, CA
- Active Since 07/11/2007
- Last Updated 01/08/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1043418023
Products in Payments
- DALVANCE (Drug) $5,426
- XERAVA (Drug) $1,786
- TEFLARO (Drug) $296.86
- AVYCAZ (Drug) $221.90
- Cresemba (Drug) $207.10
- DIFICID (Drug) $193.43
- VIBATIV (Drug) $147.18
- REBYOTA (Biological) $132.88
- MAVYRET (Drug) $125.00
- Orbactiv (Drug) $125.00
- MYOBLOC (Biological) $116.63
- CRESEMBA (Drug) $92.12
- Fetroja (Drug) $64.21
- ZERBAXA (Drug) $47.68
- LifeVest (Device) $35.48
- Arikayce (Drug) $34.34
- VOWST (Biological) $29.08
- SAMSCA (Drug) $22.52
- LEXISCAN (Drug) $21.49
- Alinity (Device) $20.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Palm Springs
Michael Jardula, Md, MD
Internal Medicine — Payments: $68,805
Internal Medicine $68,805
Michael Bagheri, Md, MD
Internal Medicine — Payments: $37,109
Internal Medicine $37,109
Ann Stapleton, Md, MD
Internal Medicine — Payments: $34,455
Internal Medicine $34,455
Elber Camacho, Md, MD
Internal Medicine — Payments: $21,044
Internal Medicine $21,044
Dr. Dimple Agarwal, M.d, M.D
Internal Medicine — Payments: $18,144
Internal Medicine $18,144
Kim Phan, D.o, D.O
Internal Medicine — Payments: $7,952
Internal Medicine $7,952